Johnson & Johnson company headlines, earnings, strategy, leadership, and market-moving business updates.
Market data may be delayed. For informational purposes only. Not investment advice.
The company reached an agreement to resolve about 76,000 lawsuits alleging its talc products caused ovarian cancer, with payments totaling as much as $5.5 billion.
THE APEX TIMES
THE APEX TIMES
The deal adds Firefly Bio’s proprietary Firelink degrader platform to Johnson & Johnson’s expanding cancer R&D efforts, the company said in a late-July update.
THE APEX TIMES
The company has asked a court to resolve tens of thousands of ovarian cancer claims tied to its talcum powder products with a proposed $5.5 billion settlement, according to a market report.
THE APEX TIMES
Interim data reported by Johnson & Johnson point to strong clinical activity for a two-drug regimen built around Tecvayli and Talvey in patients with relapsed or refractory multiple myeloma, with the trial unblinded early after the regimen produced a significant reduction in risk or events.
THE APEX TIMES
Johnson & Johnson, a long-running healthcare bellwether trading as NYSE:JNJ, has moved up modestly this year, even as investors have questioned whether the company’s momentum will translate into a sustained rally.
THE APEX TIMES
A new equity research note highlighted continued progress in Johnson & Johnson’s Innovative Medicine segment, suggesting the company’s near-to-medium term product trajectory could extend into 2027.
THE APEX TIMES
The healthcare conglomerate said its second-quarter results came in above expectations and that strength in its Innovative Medicine segment, along with pipeline progress, supports an upward revision to its 2026 outlook.
THE APEX TIMES
A recent market note argues that even if one part of Johnson & Johnson’s business is cooling, another segment is expanding in ways that could matter more for the stock’s next move.
THE APEX TIMES
The healthcare company said it is collaborating with TIME on a new branded recognition meant to highlight healthcare professionals, though details on judging and rollout were not provided in the announcement.
